Biotech Values

[DewDiligence]

UTHR acquires STDY for $4.46/sh in cash plus contingencies—a 68% premium to Friday’s close (excluding the CVR):

https://www.prnewswire.com/news-releases/united-therapeutics-to-acquire-steadymed-ltd-300638666.html

United Therapeutics Corporation and SteadyMed Ltd. announced today the signing of a definitive merger agreement under which United Therapeutics will acquire SteadyMed for $4.46 per share in cash at closing and an additional $2.63 per share in cash upon the achievement of a milestone related to the commercialization of Trevyent.

…The Board of Directors of SteadyMed has unanimously approved the merger agreement and unanimously recommends that SteadyMed shareholders adopt the merger agreement. SteadyMed shareholders owning approximately 43.3 percent of the ordinary shares of SteadyMed have entered into an agreement to vote their shares in favor of the transaction. The transaction…is expected to be completed in the third quarter of this year.

The nominal deal value is $216M.

The stock is currently trading in the high $4s due to the CVR.